BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24621372)

  • 1. High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients.
    Sato H; Hatanaka KC; Hatanaka Y; Hatakeyama H; Hashimoto A; Matsuno Y; Fukuda S; Sabe H
    Cell Commun Signal; 2014 Mar; 12():17. PubMed ID: 24621372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
    Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
    Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.
    Sabe H; Hashimoto S; Morishige M; Ogawa E; Hashimoto A; Nam JM; Miura K; Yano H; Onodera Y
    Traffic; 2009 Aug; 10(8):982-93. PubMed ID: 19416474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis.
    Hashimoto A; Hashimoto S; Ando R; Noda K; Ogawa E; Kotani H; Hirose M; Menju T; Morishige M; Manabe T; Toda Y; Ishida S; Sabe H
    PLoS One; 2011; 6(8):e23359. PubMed ID: 21858086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
    Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
    Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
    Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
    Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
    Tsutaho A; Hashimoto A; Hashimoto S; Hata S; Kachi S; Hirano S; Sabe H
    Cell Commun Signal; 2020 Jun; 18(1):101. PubMed ID: 32580737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis.
    Hashimoto S; Hirose M; Hashimoto A; Morishige M; Yamada A; Hosaka H; Akagi K; Ogawa E; Oneyama C; Agatsuma T; Okada M; Kobayashi H; Wada H; Nakano H; Ikegami T; Nakagawa A; Sabe H
    Proc Natl Acad Sci U S A; 2006 May; 103(18):7036-41. PubMed ID: 16636290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of EPB41L5, an integral component of the Arf6-driven mesenchymal program, correlates with poor prognosis of squamous cell carcinoma of the tongue.
    Otsuka Y; Sato H; Oikawa T; Onodera Y; Nam JM; Hashimoto A; Fukunaga K; Hatanaka KC; Hatanaka Y; Matsuno Y; Fukuda S; Sabe H
    Cell Commun Signal; 2016 Nov; 14(1):28. PubMed ID: 27871329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rab5c promotes AMAP1-PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion.
    Onodera Y; Nam JM; Hashimoto A; Norman JC; Shirato H; Hashimoto S; Sabe H
    J Cell Biol; 2012 Jun; 197(7):983-96. PubMed ID: 22734003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer.
    Hashimoto A; Handa H; Hata S; Tsutaho A; Yoshida T; Hirano S; Hashimoto S; Sabe H
    Cell Commun Signal; 2021 May; 19(1):54. PubMed ID: 34001163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
    Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway.
    Wakasaki T; Masuda M; Niiro H; Jabbarzadeh-Tabrizi S; Noda K; Taniyama T; Komune S; Akashi K
    Neoplasia; 2010 Oct; 12(10):789-96. PubMed ID: 20927317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Egloff AM; Rothstein ME; Seethala R; Siegfried JM; Grandis JR; Stabile LP
    Clin Cancer Res; 2009 Nov; 15(21):6529-40. PubMed ID: 19825947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIN85, a Cbl-interacting protein, is a component of AMAP1-mediated breast cancer invasion machinery.
    Nam JM; Onodera Y; Mazaki Y; Miyoshi H; Hashimoto S; Sabe H
    EMBO J; 2007 Feb; 26(3):647-56. PubMed ID: 17255943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.
    Rampias T; Pectasides E; Prasad M; Sasaki C; Gouveris P; Dimou A; Kountourakis P; Perisanidis C; Burtness B; Zaramboukas T; Rimm D; Fountzilas G; Psyrri A
    Ann Oncol; 2013 Aug; 24(8):2124-31. PubMed ID: 23406730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression.
    Alterio D; Marvaso G; Maffini F; Gandini S; Chiocca S; Ferrari A; Preda L; Rocca MC; Lepanto D; Fodor C; Volpe S; Dicuonzo S; Laudati A; Giugliano G; Ansarin M; Jereczek-Fossa BA
    Med Oncol; 2017 Jun; 34(6):107. PubMed ID: 28452036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
    Wheeler S; Siwak DR; Chai R; LaValle C; Seethala RR; Wang L; Cieply K; Sherer C; Joy C; Mills GB; Argiris A; Siegfried JM; Grandis JR; Egloff AM
    Clin Cancer Res; 2012 Apr; 18(8):2278-89. PubMed ID: 22351687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status.
    Hofman P; Butori C; Havet K; Hofman V; Selva E; Guevara N; Santini J; Van Obberghen-Schilling E
    Br J Cancer; 2008 Mar; 98(5):956-64. PubMed ID: 18268492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.